Therapeutic Vaccine with Novel Checkpoint Inhibition - Sue Currie, PhD скачать в хорошем качестве

Therapeutic Vaccine with Novel Checkpoint Inhibition - Sue Currie, PhD

Presenter: Sue Currie, PhD, Virion Therapeutics, LLC, United States Lecture: Therapeutic Vaccine with Novel Checkpoint Inhibition Presented in Session 3: Immunology and Immunotherapy International Workshop on HBV Cure 2024 Subscribe to our newsletter: https://amededu.activehosted.com/f/13 For more information, visit: https://academicmedicaleducation.com/ Upcoming meetings: https://academicmedicaleducation.com/... See next year’s edition: https://academicmedicaleducation.com/... Meeting Description The International Workshop on HBV Cure 2024 took place in San Diego, US, on Wednesday 13 November 2024 - just before the AASLD liver meeting. Since 2014, the International Workshop on HBV Cure has been a scientific platform acting as a catalyst to accelerate the progress for achieving a cure. Around the globe, more than 250 million people live with hepatitis B (HBV). The purpose of the workshop is to inform the participants about the developments in the work to find a cure for HBV. The meeting will be highly interactive with input from experts out of the arena of basic, translational, and clinical HBV research. The field of HBV treatment is undergoing major changes and is on the verge of a paradigm shift. The many new treatment options that are becoming available provide great hopes for decreasing the burden of the disease, simplifying treatment, and potentially curing and eradicating HBV infection. In order to optimize curative treatment for HBV, outstanding speakers from around the globe will share the newest therapeutic options for viral hepatitis, and experts will discuss the path forward to cure this deadly disease, leading to liver cirrhosis and liver cancer. Questions on which endpoints to use in therapeutic trials and how to combine different agents targeting the virus and/or immune system will be extensively discussed. This workshop also brings together global inter-disciplinary experts to provide a framework for how academia and industry should collaborate to achieve the goal of curing hepatitis B.